Public dataset
Recorded enzyme and transporter findings by polarity
Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.
What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
- Public rows
- 8,404
- Generated
- Schema version
- 1.3.0
Coverage
What this run contains
- Medicine–counterparty–role groups
- 8,404
- Source sentence records
- 20,358
- Asserted sentences
- 4,700
- Denied sentences
- 7,494
- Polarity not recorded
- 8,164
- Medicines represented
- 755
- Counterparties represented
- 36
- Corpus records considered
- 9,855
- All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
- inducer groups
- 617
- inhibitor groups
- 3,131
- not_recorded groups
- 3,074
- substrate groups
- 1,582
Method
How the rows were made
- A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
- A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
- Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
- Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
- The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.
Limits
Read these before using a row
- A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
- This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
- ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
- A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
- 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
- Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
- 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
- 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
- The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
- The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
- A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
- Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.
Provenance
Source examples
Abacavir · CYP3A4 inhibitor
2 asserted · 2 denied · 0 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.
Abacavir · BCRP substrate
0 asserted · 4 denied · 0 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.
Abacavir · CYP2C9 not_recorded
0 asserted · 0 denied · 2 polarity not recorded
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).
Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| medicineName | string | Recorded medicine name; not normalized for display style. |
| counterparty | string | The exact recorded counterparty spelling. |
| role | string | SUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role. |
| assertedCount | number | Sentence records whose polarity is ASSERTED. |
| deniedCount | number | Sentence records whose polarity is NEGATED. |
| polarityNotRecordedCount | number | Sentence records for which the parser did not settle assertion or denial. |
| sentences | sentence[] | Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated. |
Reader
Search and filter the rows
Showing 411–420 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 411
- Medicine slug
- aripiprazole
- Medicine name
- Aripiprazole
- Enzyme or transporter
- CYP2D6
- Role
- INHIBITOR
- Asserted sentences
- 4
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Based on simulation, a 4.5-fold increase in mean C max and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
A 3-fold increase in mean C max and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Based on simulation, a 4.5-fold increase in mean C max and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
A 3-fold increase in mean C max and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.
Projected row 412
- Medicine slug
- aripiprazole
- Medicine name
- Aripiprazole
- Enzyme or transporter
- CYP2D6
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 6
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4.
Projected row 413
- Medicine slug
- aripiprazole
- Medicine name
- Aripiprazole
- Enzyme or transporter
- CYP3A4
- Role
- INHIBITOR
- Asserted sentences
- 4
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Based on simulation, a 4.5-fold increase in mean C max and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
A 3-fold increase in mean C max and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Based on simulation, a 4.5-fold increase in mean C max and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
A 3-fold increase in mean C max and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.
Projected row 414
- Medicine slug
- aripiprazole
- Medicine name
- Aripiprazole
- Enzyme or transporter
- CYP3A4
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 4
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:d8183eaf-0093-4720-b8ed-20e570697511 (opens source in a new tab)
Aripiprazole label
Version not recorded · Effective date not recorded
Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4.
Projected row 415
- Medicine slug
- aripiprazole-lauroxil
- Medicine name
- Aripiprazole Lauroxil
- Enzyme or transporter
- CYP2D6
- Role
- INHIBITOR
- Asserted sentences
- 4
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
Based on simulation, a 4.5-fold increase in mean C max and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
After oral administration, a 3-fold increase in mean C max and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
Based on simulation, a 4.5-fold increase in mean C max and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
After oral administration, a 3-fold increase in mean C max and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.
Projected row 416
- Medicine slug
- aripiprazole-lauroxil
- Medicine name
- Aripiprazole Lauroxil
- Enzyme or transporter
- CYP2D6
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
Elimination of aripiprazole is mainly through hepatic metabolism involving CYP3A4 and CYP2D6. [see Dosage and Administration ( 2.4 )].
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
Elimination of aripiprazole is mainly through hepatic metabolism involving CYP3A4 and CYP2D6. [see Dosage and Administration ( 2.4 )].
Projected row 417
- Medicine slug
- aripiprazole-lauroxil
- Medicine name
- Aripiprazole Lauroxil
- Enzyme or transporter
- CYP3A4
- Role
- INHIBITOR
- Asserted sentences
- 4
- Denied sentences
- 0
- Polarity not recorded
- 0
- Complete sentence records
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
Based on simulation, a 4.5-fold increase in mean C max and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
- ASSERTEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
After oral administration, a 3-fold increase in mean C max and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
Based on simulation, a 4.5-fold increase in mean C max and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
- ASSERTEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
After oral administration, a 3-fold increase in mean C max and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.
Projected row 418
- Medicine slug
- aripiprazole-lauroxil
- Medicine name
- Aripiprazole Lauroxil
- Enzyme or transporter
- CYP3A4
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 2
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
Elimination of aripiprazole is mainly through hepatic metabolism involving CYP3A4 and CYP2D6. [see Dosage and Administration ( 2.4 )].
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:17a8d11b-73b0-4833-a0b4-cf1ef85edefb (opens source in a new tab)
Aripiprazole Lauroxil label
Version not recorded · Effective date not recorded
Elimination of aripiprazole is mainly through hepatic metabolism involving CYP3A4 and CYP2D6. [see Dosage and Administration ( 2.4 )].
Projected row 419
- Medicine slug
- armodafinil
- Medicine name
- Armodafinil
- Enzyme or transporter
- CYP1A2
- Role
- INDUCER
- Asserted sentences
- 0
- Denied sentences
- 2
- Polarity not recorded
- 0
- Complete sentence records
- NEGATEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
No dose adjustment is required. • Drugs Metabolized by CYP1A2 In vitro data demonstrated that armodafinil is a weak inducer of CYP1A2 in a concentration-related manner.
- NEGATEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
No dose adjustment is required. • Drugs Metabolized by CYP1A2 In vitro data demonstrated that armodafinil is a weak inducer of CYP1A2 in a concentration-related manner.
Projected row 420
- Medicine slug
- armodafinil
- Medicine name
- Armodafinil
- Enzyme or transporter
- CYP1A2
- Role
- NOT_RECORDED
- Asserted sentences
- 0
- Denied sentences
- 0
- Polarity not recorded
- 4
- Complete sentence records
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Drug Interactions In vitro data demonstrated that armodafinil weakly induces CYP1A2 and possibly CYP3A activities in a concentration-related manner and that CYP2C19 activity is reversibly inhibited by armodafinil.
- NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, in a clinical study using caffeine as a probe substrate, no significant effect on CYP1A2 activity was observed. • Drugs Metabolized by CYP2C19 In vitro data demonstrated that armodafinil is a reversible inhibitor of CYP2C19 activity.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
Drug Interactions In vitro data demonstrated that armodafinil weakly induces CYP1A2 and possibly CYP3A activities in a concentration-related manner and that CYP2C19 activity is reversibly inhibited by armodafinil.
- NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)
Armodafinil label
Version not recorded · Effective date not recorded
However, in a clinical study using caffeine as a probe substrate, no significant effect on CYP1A2 activity was observed. • Drugs Metabolized by CYP2C19 In vitro data demonstrated that armodafinil is a reversible inhibitor of CYP2C19 activity.
Access
Query or download the projection
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=410Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- role
- Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
- counterparty
- Exact recorded counterparty spelling.
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.